Prospective Ascertainment for Late Effects Among Cancer Survivors
Observational Model: Family-Based, Time Perspective: Prospective
establish a registry of DNA
For the purpose of facilitating future genetic laboratory investigations of late effects among cancer survivors. Patients in the ALTFU Program are followed for secondary malignant neoplasms and other adverse outcomes (so-called "late effects") including cardiomyopathy, pulmonary fibrosis, cardiac valvular pathology, osteoporosis, and others. The following data will be ascertained from each study participant: (1) family history information will be ascertained using the Family History Questionnaire (Appendix A); and (2) saliva or blood samples for genetic analysis.
Emily Tonorezos, MD, MPH
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan Kettering Cancer Center||New York, New York 10021|